Stay updated on Daratumumab for AML/High-Risk MDS Clinical Trial
Sign up to get notified when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.

Latest updates to the Daratumumab for AML/High-Risk MDS Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedMinor site maintenance update: the page now shows Revision: v3.3.2 (replacing v3.3.1) with no changes to study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check18 days agoChange DetectedAdded Revision: v3.3.1 and removed Revision: v3.2.0, signaling a version update that does not modify the trial details or eligibility.SummaryDifference0.1%

- Check26 days agoChange DetectedThe page no longer displays a notice about government funding and operating status; the core trial information remains unchanged.SummaryDifference0.4%

- Check40 days agoChange DetectedThe new screenshot shows minor UI adjustments and wording edits on the study page, while core content (title, NCT number, eligibility criteria, primary/secondary outcomes) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check68 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference3%

- Check76 days agoChange DetectedUpdate the page version from v3.0.2 to v3.1.0, reflecting a newer release metadata.SummaryDifference0.1%

Stay in the know with updates to Daratumumab for AML/High-Risk MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.